Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 13Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid 6Brain Neoplasms 6Prostatic Neoplasms 5Philadelphia Chromosome 5Blast Crisis 5Sarcoma 4Recurrence 4Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Stomach Neoplasms 2Polycythemia Vera 2Neurofibromatoses 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Meningioma 2

Interventions

Doxorubicin 4pazopanib 2Ifosfamide 2saracatinib 1sapanisertib 1indolepropanol phosphate 1Watchful Waiting 1TTI-621 1Sunitinib 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Polymerase Chain Reaction 1Observation 1Neoadjuvant Therapy 1MLN 8237 1Imatinib Mesylate 1HhAntag691 1Gene Expression Profiling 1Dexrazoxane 1Blotting, Western 1Albumin-Bound Paclitaxel 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Dermatofibrosarcoma × Imatinib Mesylate × Clear all
NCT00243191 2012-03-29

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
18 enrolled 7 charts
Sarcoma

Recurrence, Dermatofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡